FDA green-lights CRISPR Therapeutics, Vertex Pharmaceuticals’ gene-editing study
The agency also accepted the two companies' IND to begin the Phase I/II study of CTX001 in patients with sickle cell disease, sending CRISPR shares up more than 11 percent Thursday morning.